Skip to main content
SpringerLink
Log in

Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Apalutamide (Erleada®) is an oral selective androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. It is approved in the EU and the USA for the treatment of adult men with metastatic castration-sensitive prostate cancer (mCSPC). In a multinational, phase III study (TITAN) in this patient population, the addition of apalutamide (240 mg once daily) to androgen deprivation therapy (ADT) significantly improved median radiographic progression-free survival (rPFS), median overall survival (OS) and the median time to cytotoxic chemotherapy, while maintaining health-related quality of life (HR-QOL) and not substantially differing from placebo plus ADT in safety. Although mature OS data are awaited with interest, the addition of apalutamide to ADT extends the treatment options available for standard of care in adult men with mCSPC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Comprehensive Cancer Network. NCCN guidelines version 2.2020 prostate cancer. 2020. https://www.nccn.org. Accessed 21 Aug 2020.

  2. European Association of Urology. Prostate cancer. 2020. https://www.uroweb.org/guideline/prostate-cancer/. Accessed 21 Aug 2020.

  3. Katzenwadel A, Wolf P. Androgen deprivation of prostate cancer: leading to a therapeutic dead end. Cancer Lett. 2015;367(1):12–7.

    Article  CAS  Google Scholar 

  4. Barata P, Swami U, Agarwal N. The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. Expert Rev Anticancer Ther. 2020;20(3):147–50.

    Article  CAS  Google Scholar 

  5. Janssen-Cilag International NV. Erleada (apalutamide): EU summary of product characteristics. 2020. https://www.ema.europa.eu/. Accessed 21 Aug 2020.

  6. Janssen Products LP. ERLEADA® (apalutamide) tablets, for oral use: US prescribing information. 2020. https://www.fda.gov/. Accessed 21 Aug 2020.

  7. Al-Salama ZT. Apalutamide: a review in non-metastatic castration-resistant prostate cancer. Drugs. 2019;79(14):1591–8.

    Article  Google Scholar 

  8. Scott LJ. Apalutamide in non-metastatic castration-resistant prostate cancer: a profile of its use. Drugs Ther Perspect. 2020;36(3):97–105.

    Article  Google Scholar 

  9. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24.

    Article  CAS  Google Scholar 

  10. US National Institutes of Health. ClinicalTrials.gov identifier NCT02489318. 2020. https://www.clinicaltrials.gov/. Accessed 21 Aug 2020.

  11. Agarwal N, McQuarrie K, Bjartell A, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2019;20(11):1518–30.

    Article  CAS  Google Scholar 

  12. Ozguroglu M, Chowdhury S, Bjartell A, et al. Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: outcomes in patients (pts) with low- and high-risk disease [abstract no. 87]. J Clin Oncol. 2020;38(Suppl 6).

  13. Feng FY, Thomas S, Aguilar-Bonavide C, et al. Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN [abstract no. 5535]. J Clin Oncol. 2020;38(Suppl).

  14. European Medicines Agency. Erleada (apalutamide): assessment report. 2019. https://www.ema.europa.eu/. Accessed 21 Aug 2020.

  15. Marchioni M, Di Nicola M, Primiceri G, et al. New antiandrogen compounds compared to docetaxel in metastatic hormone sensitive prostate cancer: results from a network meta-analysis. J Urol. 2019;203(4):751–9.

    Article  Google Scholar 

  16. Ng K, Smith S, Shamash J. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting. Oncol Ther. 2020. https://doi.org/10.1007/s40487-020-00119-z.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–503.

    Article  CAS  Google Scholar 

  18. Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525–30.

    Article  CAS  Google Scholar 

  19. Chi KN, Thomas S, Agarwal N, et al. Androgen receptor (AR) aberrations in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN [abstract no. 883P]. Ann Oncol. 2019;30(Suppl 5):v347–8.

    Article  Google Scholar 

  20. Belderbos B, de Wit R, Chien C, et al. An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2018;82(3):457–68.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

During the peer review process, the manufacturer of the agent under review was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Sheridan M. Hoy

Authors
  1. Sheridan M. Hoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheridan M. Hoy.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

Sheridan Hoy is a salaried employee of Adis International Ltd/Springer Nature and declares no conflict of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

Enhanced material for this Adis Drug Evaluation can be found at https://doi.org/10.6084/m9.figshare.12838184.

The manuscript was reviewed by: P. Barata, Tulane University School of Medicine, New Orleans, LA, USA; A. Jang, Tulane University School of Medicine, New Orleans, LA, USA; M. Marchioni, Urology Unit, Department of Medical, Oral and Biotechnological Sciences, G. D’Annunzio University of Chieti, Chieti, Italy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoy, S.M. Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer. Drugs 80, 1579–1585 (2020). https://doi.org/10.1007/s40265-020-01401-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-020-01401-0

Search

Navigation